728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads

Applied BioMath, LLC Announces Quantitative Systems Pharmacology (QSP) Industry & Academia Symposium Speaker Lineup

THIS POST WAS ORIGINALLY PUBLISHED ON THIS SITE Click Here To Read Entire Article

LINCOLN, Mass., Jan. 12, 2018 /PRNewswire/ — Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis, to drug research and development, today announced the speaker lineup for the upcoming QSP Industry & Academia Symposium. The event will take place Wednesday, February 7, 2018 from 5:00 p.m. to  8:30 p.m. at the Cambridge Innovation Center in Cambridge, MA.

This QSP Industry & Academia Symposium will feature presentations from Richard Allen, PhD,  Senior Principal Scientist at Pfizer and Carissa Young, PhD, Senior Scientist at Applied BioMath along with networking opportunities.

Richard Allen, PhD, is presenting a talk titled “Assessing Fructose as a Biomarker by Modeling the Metabolic Fate of Fructose in Essential Fructosuria Subjects” in which he will discuss the development and use of a mathematical model to investigate the adaptations to altered fructose metabolism in people with a rare benign genetic deficiency in ketohexokinase (KHK). The findings have implications for drug discovery and development, suggesting that the therapeutic targeting of fructose metabolism could lead to unexpected metabolic adaptations, potentially due to a physiological response to high fructose conditions.

Carissa Young, PhD, presently a Senior Scientist at Applied BioMath, is presenting research that she completed during her Postdoc at MIT under the direction of Dr. Douglas A. Lauffenburger. Dr. Young’s talk, “3D Metastatic Breast Cancer Model Recapitulates Dormancy and Emergence,” will uncover how a 3D metastatic model composed of human hepatocytes, non-parenchymal cells, and breast cancer cell lines enabled the evaluation of tumor growth, dormancy, and emergence amongst multiple donors, as a consequence of chemotherapies and inflammatory stimuli. The results recapitulate human disease pathophysiology using an all-human ex vivo microphysiological system, which may ultimately improve therapeutic strategies that target breast cancer dormancy and emergence.

“I am passionate about fostering the QSP community and building a network of resources together. The presentations spark engaging group discussions as we continue to share challenges and best practices with one another.”

Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath

For more information about this QSP Industry and Academia Symposium, and to register, visit appliedbiomath.com/QSPIAS.

About Applied BioMath

Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development.  Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early

About The Author

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: